Morris, M. J., Loriot, Y., Beer, T. M., Higano, C. S., Armstrong, A. J., Sternberg, C. N., … Rathkopf, D. E. (2014). Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. In Journal of Clinical Oncology (Vol. 32, pp. 5054–5054). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2014.32.15_suppl.5054

Morris, Michael J., Yohann Loriot, Tomasz M. Beer, Celestia S. Higano, Andrew J. Armstrong, Cora N. Sternberg, Johann Sebastian De Bono, et al. “Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.” In Journal of Clinical Oncology, 32:5054–5054. American Society of Clinical Oncology (ASCO), 2014. https://doi.org/10.1200/jco.2014.32.15_suppl.5054.

Morris MJ, Loriot Y, Beer TM, Higano CS, Armstrong AJ, Sternberg CN, et al. Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5054–5054.

Morris, Michael J., et al. “Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo.” Journal of Clinical Oncology, vol. 32, no. 15_suppl, American Society of Clinical Oncology (ASCO), 2014, pp. 5054–5054. Crossref, doi:10.1200/jco.2014.32.15_suppl.5054.

Morris MJ, Loriot Y, Beer TM, Higano CS, Armstrong AJ, Sternberg CN, De Bono JS, Tombal BF, Noonberg SB, Mansbach HH, Bhattacharya S, Perabo F, Phung D, Rathkopf DE. Sensitivity analyses for radiographic progression-free survival (rPFS): Results from the phase 3 PREVAIL trial comparing enzalutamide to placebo. Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2014. p. 5054–5054.